Market Spotlight: Myelodysplastic Syndrome (MDS)
Market Spotlight: Myelodysplastic Syndrome (MDS)
$1,318.00
This Market Spotlight report covers the myelodysplastic syndrome market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the Myelodysplastic Syndrome (MDS) market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, probability of success, upcoming and regulatory events, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
- Datamonitor Healthcare estimates that in 2019, there were 238,000 incident cases of myelodysplastic syndrome (MDS) worldwide, and forecasts that number to increase to 313,500 incident cases by 2028.
- Approved drugs in the MDS space target DNA synthesis, angiogenesis, E3 ubiquitin ligase, the immune system, transforming growth factor-beta receptor, erythropoietin receptor, BCR-ABL fusion protein, KIT/c-KIT, platelet-derived growth factor receptor, cytidine deaminase, and DNA methyltransferase. These therapies are administered via the intravenous, oral, and subcutaneous routes.
- The greatest proportion of industry-sponsored drugs in active clinical development for MDS are in Phase II. Therapies in development for MDS focus on a wide variety of targets. The majority of pipeline drugs in the MDS space are administered via the intravenous or oral routes, with the remainder being subcutaneous or intradermal formulations.
- High-impact upcoming events for drugs in the MDS space comprise topline Phase III trial results for pevonedistat, magrolimab, and Reblozyl; topline Phase II trial results for eprenetapopt, KER-050, and MBG453; and updated Phase II/III trial results for imetelstat.
- The overall likelihood of approval of a Phase I hematologic asset is 8.7%, and the average probability a drug advances from Phase III is 58.9%. Drugs, on average, take 9.4 years from Phase I to approval, compared to 9.6 years in the overall oncology space.
- The distribution of clinical trials across Phase I–IV indicates that the vast majority of trials for MDS have been in the early and mid-phases of development, with 89% of trials in Phase I–II, and only 11% in Phase III–IV.
- The US has a substantial lead in the number of MDS clinical trials globally. France leads the major European markets, while Japan has the top spot in Asia
- Clinical trial activity in the MDS space is dominated by completed trials. Bristol Myers Squibb has the highest number of completed clinical trials for MDS, with 106 trials.
- Bristol Myers Squibb leads the industry sponsors with by far the highest overall number of clinical trials for MDS.
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
8 Subtypes
10 TREATMENT
10 Supportive therapy
10 Growth factors
10 Chemotherapy
11 Immune treatments
11 Stem cell transplant
12 EPIDEMIOLOGY
15 MARKETED DRUGS
18 PIPELINE DRUGS
28 RECENT EVENTS AND ANALYST OPINION
28 Eprenetapopt for MDS (December 28, 2020)
29 Guadecitabine for MDS (October 14, 2020)
30 Estybon (Intravenous) for MDS (August 24, 2020)
32 Onureg for MDS (June 12, 2020)
33 Pevonedistat for MDS (May 29, 2020)
35 Eprenetapopt for MDS (December 9, 2019)
37 Inqovi for MDS (December 9, 2019)
38 Magrolimab for MDS (December 9, 2019)
40 MBG453 for MDS (December 9, 2019)
41 Venclexta for MDS (December 9, 2019)
42 Vidaza for MDS (December 9, 2019)
45 KEY UPCOMING EVENTS
46 KEY REGULATORY EVENTS
46 Krka, Accord And Xeris Pick Up European Nods
46 Takeda Aims To Take Higher-Risk MDS Therapy Beyond Monotherapy
46 Keeping Track: US FDA Set For Speed With Approvals Of Inqovy, Rukobia, Dojolvy, Phesgo; Keytruda Loses Chance At AA In HCC
46 Crunch Time At EMA For Luspatercept And Glasdegib
48 PROBABILITY OF SUCCESS
49 LICENSING AND ASSET ACQUISITION DEALS
49 Medexus Pharmaceuticals Licenses Exclusive Rights To Commercialize medac’s Treosulfan
49 Agios Sells Cancer Portfolio To Servier To Focus On Genetic Diseases
49 Gilead Calls Forty Seven Buyout Complementary To Kite, Other IO Efforts
50 REVENUE OPPORTUNITY
52 CLINICAL TRIAL LANDSCAPE
53 Sponsors by status
54 Sponsors by phase
55 Recent events
57 BIBLIOGRAPHY
57 Prescription information
59 APPENDIX
LIST OF FIGURES
14 Figure 1: Trends in incident cases of MDS, 2019–28
18 Figure 2: Overview of pipeline drugs for MDS in the US
18 Figure 3: Pipeline drugs for MDS, by company
19 Figure 4: Pipeline drugs for MDS, by drug type
19 Figure 5: Pipeline drugs for MDS, by classification
29 Figure 6: Eprenetapopt for MDS (December 28, 2020): Phase III – Frontline (w/Azacitidine)
30 Figure 7: Guadecitabine for MDS (October 14, 2020): Phase III – ASTRAL-3
32 Figure 8: Estybon (Intravenous) for MDS (August 24, 2020): Phase III – INSPIRE (HR-MDS)
33 Figure 9: Onureg for MDS (June 12, 2020): Phase III – 003 (Low-Risk)
35 Figure 10: Pevonedistat for MDS (May 29, 2020): Phase II – w/Azacitidine
38 Figure 11: Inqovi for MDS (December 9, 2019): Phase III – ASCERTAIN (vs. Decitabine)
40 Figure 12: Magrolimab for MDS (December 9, 2019): Phase Ib – w/Azacitidine (AML/MDS)
44 Figure 13: Vidaza for MDS (December 9, 2019): Phase II – w/Durvalumab
45 Figure 14: Key upcoming events in MDS
48 Figure 15: Probability of success in the hematologic pipeline
52 Figure 16: Clinical trials in MDS
52 Figure 17: Top 10 drugs for clinical trials in MDS
53 Figure 18: Top 10 companies for clinical trials in MDS
53 Figure 19: Trial locations in MDS
54 Figure 20: MDS trials status
55 Figure 21: MDS trials sponsors, by phase
LIST OF TABLES
13 Table 1: Incident cases of MDS, 2019–28
16 Table 2: Marketed drugs for MDS
20 Table 3: Pipeline drugs for MDS in the US
28 Table 4: Eprenetapopt for MDS (December 28, 2020)
29 Table 5: Guadecitabine for MDS (October 14, 2020)
31 Table 6: Estybon (Intravenous) for MDS (August 24, 2020)
32 Table 7: Onureg for MDS (June 12, 2020)
34 Table 8: Pevonedistat for MDS (May 29, 2020)
36 Table 9: Eprenetapopt for MDS (December 9, 2019)
37 Table 10: Inqovi for MDS (December 9, 2019)
39 Table 11: Magrolimab for MDS (December 9, 2019)
41 Table 12: MBG453 for MDS (December 9, 2019)
42 Table 13: Venclexta for MDS (December 9, 2019)
43 Table 14: Vidaza for MDS (December 9, 2019)
50 Table 15: Historical global sales, by drug ($m), 2015–19
51 Table 16: Forecasted global sales, by drug ($m), 2021–25
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Market Spotlight: Attention Deficit Hyperactivity Disorder (ADHD) 
Sign up to the